Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
US-2016215286-A1 · Jul 28, 2016 · US
Icariin derivatives
US2020354331A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020354331-A1 |
| Application number | US-201916444564-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 18, 2019 |
| Priority date | Jan 23, 2014 |
| Publication date | Nov 12, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.
First claim
Opening claim text (preview).
1 - 19 . (canceled) 20 . A method of treating myelodysplastic syndrome comprising: administering to the subject a therapeutically effective amount of any one of compounds II, IIA-A, IV-A, V-A, VI-A, or VI-A wherein R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently chosen from alkyl optionally substituted with carbonyl, alkoxyl, halogen, hydroxyl, or nitro. 21 . The method of claim 20 , wherein the compound is ICT 22 . The method of claim 20 , wherein the compound decreases the accumulation and activation of myeloid derived suppressor cells. 23 . A method of inhibiting myeloid derived suppressor cells in a subject with cancer, comprising: administering to the subject a therapeutically effective amount of any one of compounds II, IIA-A, IV-A, V-A, VI-A, or VI-A wherein R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently chosen from alkyl optionally substituted with carbonyl, alkoxyl, halogen, hydroxyl, or nitro. 24 . The method of claim 23 , wherein the compound is ICT
Assignees
Inventors
Classifications
with oxygen atoms directly attached in position 3, e.g. anthocyanidins · CPC title
Antineoplastic agents · CPC title
- C07D311/30Primary
not hydrogenated in the hetero ring, e.g. flavones · CPC title
specific for leukemia · CPC title
Benzo[b]pyran-4-ones · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020354331A1 cover?
- Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.
- Who is the assignee on this patent?
- H Lee Moffitt Cancer Ct & Res
- What technology area does this patent fall under?
- Primary CPC classification C07D311/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Nov 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).